QREDO
4.2.2022 17:47:04 CET | Business Wire | Press release
Qredo , the decentralized Layer 2 infrastructure for the custody and settlement of digital assets, today announced the close of one of the largest Series A rounds completed to date in crypto and blockchain-related markets.
Qredo’s $80 million USD Series A raise was led by 10T Holdings , the crypto investment firm managed by investors Dan Tapiero, Stan Miroshnik and Michael Dubilier. The round includes a diverse group of strategic investors Coinbase Ventures , Avalanche and Terra , and top tier financial investors Kingsway Capital , HOF Capital , Raptor Group and GoldenTree Asset Management . The Series A raise brings Qredo’s valuation to $460 million USD.
“The fact we’ve won support from some of the biggest and smartest investors in crypto is a clear validation of Qredo’s long-term focus and mission,” said Anthony Foy, Qredo CEO. “The Qredo solution provides institutions with a secure, cost-efficient, and compliant way to engage fully with digital assets and DeFi. We’re now in an excellent position to seize opportunities, take market share, and demonstrate the powerful value of decentralized custody.”
Qredo’s Layer 2 protocol enables instant cross-chain swaps and settlement on supported blockchains — with none of the frictional costs associated with Layer 1 transactions. Its decentralized multi-party computation (MPC) removes the vendor risk and the single points of failure associated with centralized custody solutions and traditional private key management.
Qredo has raised $120mm in the last 12 months. As with its seed round in May 2021 and Token Private Sale in June 2021, Qredo has attracted both financial and strategic investors. The strategic investors will also be building solutions on Qredo for their customers, bringing the next wave of user growth to the network.
Qredo’s Series A also marks a year of operational momentum. In October 2021, Qredo's groundbreaking integration with MetaMask Institutional began enabling users to securely participate in new DeFi innovations such as accessing ‘cross-chain’ liquidity pools and trading collateralized derivatives across multiple chains. A few weeks later, Qredo became one of a small number of technology partners chosen to bring forth the next generation of Bitcoin and blockchain-related applications in El Salvador.
“Infrastructure is a key battleground for scaling crypto adoption,” said Dan Tapiero, Founder and CEO of lead investor 10T Holdings. “Qredo’s distributed architecture and unique implementation of MPC is a game-changer for the secure custody and settlement of crypto assets. Qredo is a project that has the drive, resources, and technological edge to support the complex and evolving needs of its users — now and into the future.”
Qredo’s Series A includes $60mm of primary capital and $20mm from secondary investors. The funds raised will be used to fuel the next steps of Qredo’s growth. This includes future acquisitions, further development of Qredo functionality for retail users, and facilitating Qredo’s geographic expansion.
The full group of investors includes: 10T Holdings, Kingsway Capital, Coinbase Ventures, Ava Labs, Terraform Labs, GoldenTree Asset Management, HOF Capital, Tokentus Investment AG, SVK Crypto, GMF Capital, Rovida Kruptos Assets Limited, Vectr Fintech, Kestrel 0x1, Kenetic Capital, Nural Capital First Light (US) LP, Raptor Group, Alumni Ventures Blockchain Fund, and Liberty City Ventures.
Galaxy Digital served as exclusive financial advisor to Qredo and sole placement agent for the financing round.
About Qredo
Qredo
is a digital asset management infrastructure and product suite designed to unlock new opportunities for institutional investors in cryptocurrencies and decentralized finance. Qredo includes a novel Layer 2 blockchain protocol that enables users to seamlessly transfer and settle Bitcoin, Ethereum and other leading cryptocurrencies. Qredo’s advanced Gen 2.0 Multi-Party Computation (MPC) provides tier-1 bank security and eliminates the anxiety of private key management. Qredo’s network is designed to enable institutional investors to secure, settle, and access digital liquidity pools and participate in new innovations across DeFi. Follow Qredo on LinkedIn
and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220204005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom